New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
06:38 EDTONCYOncolytics Biotech reports 2013 EPS (28c), consensus (31c)
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
06:36 EDTONCYOncolytics announces series of posters to be made at AACR Annual Meeting
Subscribe for More Information
April 17, 2015
06:31 EDTONCYOncolytics receives ODD by FDA for Reolysin
Oncolytics Biotech announced that the FDA has granted an Orphan Drug Designation, or ODD, for its lead product candidate, Reolysin, for the treatment of malignant glioma. The company applied for an ODD for pediatric high grade gliomas, or HGG, however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages. In three previous brain cancer studies including gliomas, Reolysin has been shown to infect a variety of brain tumors when delivered intravenously.
April 16, 2015
09:14 EDTONCYOncolytics granted orphan status for malignant glioma treatment
The FDA granted Oncolytics orphan status for its treatment of malignant glioma, Reolysin. .
April 15, 2015
06:35 EDTONCYOncolytics Biotech's Reolysin shows positive results in pancreatic cancer
Subscribe for More Information
06:34 EDTONCYOncolytics Biotech presents Reolysin data at UK Immuno-oncology meeting
Oncolytics Biotech announced that Dr. Matt Coffey, COO, made a presentation titled "Reolysin and Immune Therapy: Rationale for Combination Therapy" at the Royal Society of Medicine's Immuno-oncology: Using the Body's Own Weapons conference, held in London, UK. The presentation included data from a single arm clinical study examining the use of Reolysin in combination with gemcitabine in patients with advanced pancreatic cancer, PD-1 and PD-L1 up regulation data from a single arm clinical study examining the use of Reolysin in patients with primary glioblastomas or brain metastases, as well as preclinical data. Highlights of new data presented include: Clinical evidence that Reolysin treatment results in immunological changes to both the tumor cells and the tumor microenvironment that is conducive to novel immune targeting interventions; and Updated results from the REO 017 study, in which pancreatic cancer patients received combination therapy with Reolysin and gemcitabine demonstrated a median overall survival of 10.2 months, and one- and two-year survival rates of 45% and 24%, respectively.
April 7, 2015
06:32 EDTONCYOncolytics Biotech announces filing for ODD with FDA for Reolysin
Subscribe for More Information
06:32 EDTONCYOncolytics Biotech submitts Orphan Drug Designation for Reolysin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use